KeyCorp Cuts LifeMD (NASDAQ:LFMD) Price Target to $8.00

LifeMD (NASDAQ:LFMD) had its price target trimmed by KeyCorp from $12.00 to $8.00 in a report issued on Wednesday, MarketBeat Ratings reports. The firm currently has an overweight rating on the stock.

LFMD has been the topic of several other reports. BTIG Research cut their price target on shares of LifeMD from $18.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of LifeMD in a research report on Wednesday, October 8th. Lake Street Capital reduced their target price on LifeMD from $14.00 to $8.00 and set a “buy” rating for the company in a report on Tuesday. Mizuho dropped their price target on LifeMD from $8.00 to $6.00 and set a “neutral” rating on the stock in a research note on Wednesday. Finally, B. Riley cut their price target on LifeMD from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, LifeMD currently has a consensus rating of “Hold” and an average price target of $9.43.

LifeMD Trading Up 3.8%

Shares of LFMD stock opened at $3.85 on Wednesday. The firm has a fifty day moving average price of $5.88 and a 200 day moving average price of $8.59. The company has a market cap of $185.32 million, a P/E ratio of -22.65 and a beta of 1.57. LifeMD has a 12 month low of $3.43 and a 12 month high of $15.84.

LifeMD (NASDAQ:LFMD) last released its quarterly earnings data on Monday, November 17th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.04). The firm had revenue of $60.17 million during the quarter, compared to analyst estimates of $62.07 million. During the same quarter in the prior year, the firm posted $0.09 EPS. LifeMD has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. On average, equities analysts forecast that LifeMD will post -0.56 EPS for the current year.

Insiders Place Their Bets

In other LifeMD news, insider Nicholas P. Alvarez sold 75,000 shares of LifeMD stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $5.92, for a total value of $444,000.00. Following the transaction, the insider directly owned 605,000 shares in the company, valued at approximately $3,581,600. This trade represents a 11.03% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 18.40% of the company’s stock.

Institutional Investors Weigh In On LifeMD

Several hedge funds have recently modified their holdings of the stock. CWM LLC grew its position in LifeMD by 17.5% in the 1st quarter. CWM LLC now owns 9,050 shares of the company’s stock valued at $49,000 after buying an additional 1,351 shares during the last quarter. Nisa Investment Advisors LLC raised its position in LifeMD by 148.5% during the 2nd quarter. Nisa Investment Advisors LLC now owns 3,656 shares of the company’s stock worth $50,000 after buying an additional 2,185 shares during the last quarter. Quarry LP purchased a new position in LifeMD during the 3rd quarter worth $52,000. Tower Research Capital LLC TRC lifted its stake in shares of LifeMD by 110.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock worth $64,000 after acquiring an additional 2,452 shares during the period. Finally, King Wealth Management Group purchased a new stake in shares of LifeMD in the third quarter valued at about $68,000. 35.52% of the stock is owned by institutional investors and hedge funds.

About LifeMD

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.